Navigation Links
Neogen comments on SenesTech
Date:7/24/2014

LANSING, Mich., July 24, 2014 /PRNewswire/ -- Neogen Corporation (Nasdaq: NEOG) advised market analysts today that future forecasts of its potential revenue from new rodenticide research are premature. In its regular quarterly conference call to investors and analysts on July 22, 2014, Neogen's CEO commented about several new developments when questioned by analysts regarding this research.

"It was my intent Tuesday at our conference call to answer questions about the potential of a new type of rodenticide, but certainly not to give any indication of size of that market," said James Herbert, Neogen's chief executive officer and chairman. "When asked about market studies, I declined any market projections since it is our intention to market this rodenticide in combination with our other current formulas. I also indicated that we hoped to submit application for approval to the U. S. Environmental Protection Agency sometime this summer, and though optimistic of eventual approval, could not forecast timing."

Neogen issued a press release on June 16, 2014, that it had licensed patents to a rodenticide aimed at controlling rodents through fertility control. The company indicated it was currently doing more beta site testing in field situations with natural rodent populations and was still awaiting those results before making any further investments.   

The company made these comments because of market reactions to published research on Wednesday that drove up both the price of the stock and volume. 

Neogen Corporation develops and markets products dedicated to food and animal safety. The company's Food Safety Division markets dehydrated culture media, and diagnostic test kits to detect foodborne bacteria, natural toxins, food allergens, drug residues, plant diseases and sanitation concerns. Neogen's Animal Safety Division is a leader in the development of animal genomics, along with the manufacturing and distribution of a variety of animal healthcare products, including diagnostics, pharmaceuticals, veterinary instruments, wound care and disinfectants.

CONTACT:
Steven J. Quinlan, Vice President & CFO
517/372-9200 


'/>"/>
SOURCE Neogen Corporation
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. Neogen Corporation Announces 2nd Quarter Results Conference Call
2. Neogen Reports Second Quarter Results
3. Neogen Launches Fully Quantitative Lateral Flow Test for DON
4. Neogen launches the fastest molecular pathogen test
5. Neogen acquires Igenity from Merial
6. Neogen Corporation Announces Year-End Results Conference Call
7. Neogen reports year end results
8. Neogen Corporation Announces 1st Quarter Results Conference Call
9. Neogen reports 30% increase in quarterly net income
10. Neogen Corporation Announces 3rd Quarter Results Conference Call
11. Neogen launches rapid tests for ractopamine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... ... May 24, 2017 , ... Patient ... developed with Wi-Fi connectivity to reduce the amount of wiring in a healthcare ... addition, compact mobile devices including infusion pumps, heart and hypertension monitoring, glucose monitoring, ...
(Date:5/23/2017)... ... 2017 , ... Firmex today announced the general ... for organizations to send and gather large files and confidential documents beyond the ... size limitations. , Using the same market-tested infrastructure as Firmex’s flagship Virtual ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... source of human cardiovascular cells for research and the development of cardiac ... possible to generate large numbers of cardiomyocytes (hPSC-CMs). Due to varying differentiation ...
(Date:5/23/2017)... ... May 22, 2017 , ... NetDimensions has been ranked as ... Globe™ for Corporate Learning, 2017. , Aragon Research defines Leaders as organizations who ... perform against those strategies. NetDimensions’ ranking as a Leader due to its strengths ...
Breaking Biology Technology:
(Date:4/5/2017)... Today HYPR Corp. , leading innovator ... of the HYPR platform is officially FIDO® Certified ... architecture that empowers biometric authentication across Fortune 500 enterprises ... over 15 million users across the financial services industry, ... product suites and physical access represent a growing portion ...
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
(Date:3/30/2017)... Trends, opportunities and forecast in this market ... (fingerprint, AFIS, iris recognition, facial recognition, hand geometry, vein ... use industry (government and law enforcement, commercial and retail, ... others), and by region ( North America ... Pacific , and the Rest of the World) ...
Breaking Biology News(10 mins):